A cheap home test that catches what an annual physical mostly misses: how much physical reserve you actually have. A weak or falling reading is often the first sign of quiet deconditioning, sub-clinical illness, or early frailty — soon enough to do something about it. Two minutes a year, one number, kept in a note on your phone.
The forearm muscles do the squeezing, but the predictive power doesn't come from your forearms. It comes from what your forearms travel with. People with stronger hands also tend to have more muscle everywhere else, better-functioning hearts and lungs, less hidden inflammation, and intact wiring between brain and muscle. None of that is cheap to measure. A handle and a dial costs $50.
So a dynamometer reading is a cheap surrogate for an expensive question: how much working machinery does this body still have? That's why three major medical bodies have built screening tools around it — not because the forearms themselves matter especially, but because a single number, taken in two minutes, integrates more upstream signals than any other single test you can do at home.
How much it predicts
Two studies anchor this. The first followed 140,000 adults across 17 countries on four continents. The second tracked half a million people in the UK. Both asked the same question — does a grip-strength reading taken once, in middle or older age, predict who dies in the next few years? Both said yes, decisively, with the same answer.
This isn't a fringe finding. A meta-analysis pooling fourteen earlier cohorts found the weakest quartile of adults had roughly 67% higher all-cause death rates than the strongest (Cooper et al. 2010). A more recent pooling of ~2 million people put the dose-response on a curve with no upper plateau — every kilogram of grip you have above the population average buys you something, every kilogram below costs you something (García-Hermoso et al. 2018). The reading reliably picks up sub-clinical disease your annual physical missed, deconditioning your activity tracker isn't measuring, and frailty your face hasn't shown yet.
What the untracked decline looks like
The person whose grip slides from the middle of their age band to the bottom of it over a decade rarely notices the slide. Their work doesn't require squeezing. They don't carry heavy bags. The first time it shows up in their life is when a suitcase wins, or a jar wins, or — later — when a sidewalk wins.
By the time the felt symptom arrives, the marker has been bad for years. The aunt who fell, broke a hip, and never came home from the rehab facility — her grip strength was likely already below the population threshold five years before the fall, and nobody had looked. The uncle whose heart attack at 62 felt sudden — his grip had been on the steeper part of the decline curve since his early fifties, alongside the lipid panel and the blood pressure his doctor was actually tracking (Leong et al. 2015). None of this is about the hand. The hand was the cheap window into a body that was quietly burning down its reserves.
The point of measuring isn't to fix grip strength. It's to see the decline early enough that the response — resistance training, protein adequacy, a workup for what else might be going on — has time to matter.
How to do it
Buy a hydraulic hand dynamometer. Sit down. Squeeze. Write the number down. Do this once a year and keep the readings in a note on your phone.
You're looking for two things over time. Where you are — a rough sex- and age-band check against population norms (around 27 kg is the low threshold for older men, 16 kg for older women in the European guidelines (Cruz-Jentoft et al. 2019); the Asian cut-offs sit a touch higher at 28 and 18 kg (Chen et al. 2020)). And where you're heading — a 4 kg drop over three years is a louder signal than any single year's absolute number, especially under age 60.
What most guides get wrong
"If my grip is low, I should train my grip." No. A few weeks of dedicated gripper work — those squeezable handles, dead hangs, finger exercises — will push your dynamometer number up several kilograms without changing the underlying thing the number was measuring. You've improved the scoreboard, not the team. The honest response to a low reading is whole-body resistance training (legs and back, where most muscle lives), enough protein, and a conversation with your doctor about what else might be going on. Squeezing a gripper is fine, but treat it as wrist-and-forearm exercise, not as health insurance.
"Stronger grip causes longer life." Probably partly. Genetic studies of inherited grip strength do suggest a real protective effect on heart disease, but the effect is much smaller than the headline numbers from the population studies. Most of what you're seeing in those headlines is grip strength reflecting a body that's doing well across many other dimensions, not grip strength itself doing the work. The marker is still useful — what matters is whether you can spot a trend, not whether the trend is causal.
"The cut-offs apply to me." The published thresholds — 27 kg, 16 kg, 28 kg, 18 kg — were calibrated on adults over 65. They're the line at which the European and Asian guidelines start calling someone weak enough to investigate (Cruz-Jentoft et al. 2019). If you're 35, hitting those numbers tells you almost nothing — you should be far above them. What matters at 35 is starting a record so that at 55, you have twenty years of data to read a trend in.
Who benefits most from measuring
If you're over 60: the test does the most for you. The published thresholds were built on people your age, and a single low reading is genuine grounds to talk to your doctor about a frailty workup — the formal frailty definition that geriatricians use treats weak grip as one of its five core criteria (Fried et al. 2001). The conversation that follows is the point: deconditioning, sub-clinical disease, malnutrition, depression — all of them depress grip, and several of them are treatable.
If you're 40–60: this is when starting a record pays off most. You probably feel fine, your reading is probably above any clinical cut-off, and a single number on its own isn't telling you much. But the curve over the next twenty years is exactly what would have caught your future heart attack early — and that curve only exists if you start logging now. One reading a year, kept in a phone note.
If you're under 40: nice to have, mostly. A baseline is useful — it gives your 60-year-old self a starting line. But the predictive signal at your age is weak, and you have higher-leverage things to be doing (sleep, training, food).
Sex matters for the cut-off only. The relationship between grip and outcomes runs roughly parallel for men and women — what differs is the absolute number, not the slope of the curve.
Where this goes wrong in practice
- Reading the number without a trajectory. A single grip-strength reading at age 45, with nothing to compare it to, is barely useful. The signal is the slope, not the point. Start logging early so a future reading has something to land against.
- Wrong position, wrong number. Standing instead of sitting, elbow straight instead of bent, holding the handle wrong — each can shift the reading by several kilograms. Use the same protocol each year or the trend you're tracking is mostly noise.
- Toy dynamometer. A spring-loaded plastic squeezer from a sporting-goods aisle drifts and lies. A hydraulic dial dynamometer at $40 doesn't. The cheaper false economy is the more expensive mistake.
- Treating "low for age" as a diagnosis. A low reading is a prompt to investigate, not a verdict. The actual cause might be a thyroid problem, a vitamin deficiency, untreated depression, an undiagnosed heart issue, or just six months on the couch. The dynamometer doesn't know which — your doctor needs to find out.
- Chasing the proxy. Discovering grip strength as a biomarker and then training only grip strength is the most common mistake in this whole area. The number is reflecting your overall body. Train your overall body.
What changes if you do this
The first year: almost nothing. You spent $50 on a dial, squeezed it three times each hand, wrote 42 kg in a phone note, and got on with your day. The dial sits in a drawer.
Year five: you have a curve. You can see whether you're holding steady, drifting down a little, or losing ground faster than the population average for your age. That curve is something no other home test gives you for $10 a year of attention.
Year fifteen: the curve might have caught something nobody else was looking for. Three readings in a row down by 2–3 kg apiece, in your late fifties, prompts the workup that finds the sub-clinical heart problem, or the malnutrition, or the slow muscle loss that hasn't shown up in the mirror yet. The cardiac event that would have happened in your mid-sixties either doesn't, or arrives somewhere you're better prepared for it. Your friends start losing parents to hip fractures; you don't. None of this is dramatic. That's the payoff: it's the falls that didn't happen, the heart attacks that arrived a decade later, the years you spent independent because you saw the drift early enough to push back.
The catch: the payoff is in the looking, not the squeezing. If you don't log it, you don't have a curve. If you have a curve and don't act on a bad trend, you have a sadder record of your decline. The work that actually pays the dividends — resistance training, eating enough protein, addressing the underlying causes a workup turns up — lives in other entries. This one just hands you the early-warning system.
Related entries to look at next: resistance training (the main response to a declining curve), protein intake (the nutritional half of the same response), VO2max testing (the cardiovascular equivalent of this measurement — a different cheap-ish biomarker with a similar trajectory story), and routine bloodwork (the parallel layer of cheap measurements worth tracking annually from your forties on).
- — Weak grip is the warning that muscle is slipping away. Creatine plus lifting is the cheapest way to hold onto it as you age.
- — Carrying real loads is one of the everyday habits that keeps the grip number from sliding.
- — Another two-minute home test that predicts the next decade — pair them for a fuller picture.
- — Grip is a two-minute proxy for whole-body muscle; a DEXA scan measures that muscle and bone directly when you want the full picture.
- — If your grip number is sliding, resistance training is the lever that moves it back up.
- — Like grip, your aerobic engine size is one of the strongest single predictors of lifespan.
Substance and claimed effects
Hand grip strength, measured in kilograms of isometric force using a calibrated hydraulic dynamometer (typically Jamar; Smedley and Takei devices give comparable values when the protocol is standardised). The reading is treated as a global proxy for whole-body muscular strength and, more broadly, as a low-cost integrator of musculoskeletal reserve, cardiovascular fitness, and neuromuscular health. Claimed consequences across the catalogue's dimensions: predicts all-cause and cardiovascular mortality (longevity); predicts incident frailty, sarcopenia, disability, and falls (longevity, health_short_term); identifies undiagnosed sarcopenia and frailty in older adults under EWGSOP2 and AWGS thresholds (longevity, health_short_term); is a stronger predictor of mortality than systolic blood pressure in some cohorts (Leong et al. 2015); covaries with cognitive decline and incident dementia at population scale (focus, mood). The entry's substance is the measurement — using grip as a check-engine light on overall musculoskeletal reserve — not training to improve it; training is a downstream response that lives in resistance-training entries.
Evidence by addressing question
Mechanism
Science. Grip strength reflects motor-unit recruitment in the forearm flexors, but its predictive value at population scale comes from what it co-varies with rather than what the forearm muscles themselves do. Whole-body skeletal-muscle strength correlates strongly with grip across age and sex, so the dynamometer reading acts as a cheap surrogate for a quantity (total muscular strength) that is otherwise expensive to measure (Roberts et al. 2011; Sayer & Kirkwood 2015). The current consensus framing — reinforced by EWGSOP2 making grip the primary screening criterion for sarcopenia rather than muscle mass — is that strength integrates a chain of upstream inputs (motor-neuron density, mitochondrial function, anabolic signalling, capillarisation) better than mass does, which is why dynapenia tracks outcomes more tightly than sarcopenia-by-DXA (Cruz-Jentoft et al. 2019).
Mechanism — why it predicts cardiovascular events. Low grip co-segregates with insulin resistance, chronic low-grade inflammation (elevated CRP, IL-6), elevated arterial stiffness, and reduced cardiorespiratory fitness. Each of these is an independent CVD risk pathway; grip strength is downstream of all of them. Two-sample Mendelian-randomisation studies using UK Biobank-derived genetic instruments for handgrip report a protective causal effect of strength on coronary artery disease and atrial fibrillation, which suggests at least part of the association is not pure confounding — though the genetic-instrument design has known weaknesses and the causal effect is much smaller than the observational hazard ratio.
Mechanism — why it predicts mortality more broadly. Beyond CVD, low grip correlates with reduced respiratory muscle strength (predicting pneumonia and COPD mortality), with fall risk and post-fall mortality, and with delayed surgical recovery and hospital-acquired complications. Each pathway is independently consequential; the dynamometer reading captures the sum.
Evidence
Science — the anchor cohorts. The PURE study (Leong et al. 2015) followed 139,691 adults across 17 high-, middle-, and low-income countries for a median 4.0 years. Each 5 kg lower grip strength was associated with a 16% higher risk of all-cause mortality (hazard ratio 1.16, 95% CI 1.13–1.20), 17% higher cardiovascular mortality, 17% higher non-cardiovascular mortality, 7% higher incident MI, and 9% higher incident stroke. In that cohort grip strength out-predicted systolic blood pressure for all-cause and cardiovascular death. The UK Biobank analysis of ~500,000 participants (Celis-Morales et al. 2018) replicated and extended the finding: each 5 kg lower grip predicted higher all-cause mortality (HR 1.20 in men, 1.20 in women) and higher incidence of cardiovascular disease, COPD, all-cancer, and several site-specific cancers; associations attenuated only modestly after adjusting for body size, physical activity, and major comorbidities.
Science — meta-analyses. Cooper et al. (BMJ 2010) pooled 14 grip-strength cohorts and reported that the weakest quartile had ~1.67× the all-cause mortality of the strongest, a similar effect size to that later seen in PURE and UK Biobank. García-Hermoso et al. (2018) meta-analysed ~2 million apparently-healthy adults and found a consistent dose-response between higher muscular strength (with grip as the most common measure) and lower all-cause mortality, with the effect persisting across age bands. Subsequent dose-response work has located inflection points around 26 kg for men and 16 kg for women below which the mortality slope steepens.
Practice / clinical consensus. EWGSOP2 (Cruz-Jentoft et al. 2019) made low grip strength the primary screening criterion for sarcopenia (cut-offs <27 kg for men, <16 kg for women), demoting muscle-mass measurement to a confirmation step. AWGS 2019 (Chen et al. 2020) set higher cut-offs for Asian populations (<28 kg men, <18 kg women) and recommended grip-based case-finding in primary care. Fried's frailty phenotype (Fried et al. 2001), the most widely used frailty operationalisation, uses low grip — adjusted for sex and BMI — as one of its five criteria.
Community / lay evidence. Health and longevity media (Attia, Lyon, Huberman, others) treat grip as the cheap home biomarker the labs miss; consumer dynamometers (~$25) have a visible Amazon presence with mass-market reviews. This signal is downstream of the literature, not independent of it, so it adds little weight — but it does explain why the measurement is reaching general readers, and is part of why an entry on it earns its place in this catalogue.
Protocol
Practice. The Southampton protocol (Roberts et al. 2011) is the de facto standard adopted by the EWGSOP, NHANES, and most major epidemiological cohorts: seated, back supported, shoulders adducted with elbow at 90° and forearm in neutral, three squeezes per hand alternating, maximal effort, the highest of the six readings recorded. The Jamar hydraulic dynamometer is the reference instrument; Smedley and Takei devices give similar values when zeroed correctly. Verbal encouragement is standardised (a brief "squeeze as hard as you can"). Position drift matters: standing rather than seated, elbow extended rather than 90°, or a single trial rather than best-of-three each shift the reading by several kilograms.
Science — what the reading actually means. Sex- and age-stratified reference values from the Bohannon Jamar meta-analysis and the JOSPT 2018 US reference set anchor "low" to roughly the lower 95% CI bound for one's age band. Population peaks are 30–49 years in men, 40–49 in women, with a steady decline thereafter accelerating after age 65.
Contraindications
Active hand or wrist pathology (acute fracture, tendinitis flare, recent carpal-tunnel release, recent flexor-tendon repair) precludes valid measurement until healed. Severe rheumatoid arthritis, Dupuytren's contracture, and advanced peripheral neuropathy distort the reading in a direction that doesn't reflect global muscular reserve. No systemic contraindications to measurement itself — the test is sub-maximal in cardiovascular terms.
Misconceptions
1. "It's a forearm fitness test." The forearm flexors execute the measurement; the predictive power is borrowed from the whole-body correlate. Reading the dynamometer as a hand-strength score (rather than as a global reserve proxy) misses what the measurement is doing.
2. "If grip is low, train grip." Targeted grip work (squeezers, captains-of-crush, hangs) raises the dynamometer reading several kilograms within weeks without raising the underlying global muscular strength the reading was acting as a proxy for. Treating the proxy as a target Goodharts the marker — and field guidance reflects this: rehabilitative-strength guidelines note that grip strength does not change appreciably with traditional resistance training and is better treated as a reflection of overall strength than as a primary training target. The honest response to a low reading is whole-body resistance training and protein adequacy, not isolated grip work.
3. "Grip strength is fully causal." Mendelian-randomisation studies support a real causal arm for cardiovascular events, but the observational hazard ratios bake in a large dose of confounding by overall fitness, body composition, and sub-clinical disease. The marker is informative whether or not it is causal — and the catalogue should not over-claim causation.
4. "Universal cut-offs." Cut-offs are population-calibrated. EWGSOP2 thresholds (<27/<16 kg) underestimate weakness in Asian populations where AWGS uses <28/<18 kg; both are weighted to older adults and aren't the right yardstick for a 30-year-old.
Audience
The literature is densest in the 60+ cohort, where grip both predicts incident frailty and underpins the sarcopenia diagnosis. The 40–59 band has the largest gain from baseline measurement: trajectories diverge here and trend data over a decade have more predictive power than a single reading at 70. Under 40, a single reading is mostly a sanity check; trajectory is the signal. Sex matters for cut-off interpretation only — the slope of mortality vs grip strength is similar in men and women within population strata.
Failure modes
The most common failure is reading the number without a trajectory. A single low reading in a 45-year-old without baseline tells you little about that person's mortality risk relative to themselves; the same reading repeated annually, with a 4 kg drop over three years, tells you a great deal — and is the use case that actually changes behaviour. Other failure modes: wrong dynamometer position (standing, elbow extended) inflates or deflates the reading by several kg; using a spring-loaded toy dynamometer instead of a calibrated hydraulic; treating "low for age" as immediate disease rather than a prompt to investigate causes (deconditioning, malnutrition, sub-clinical disease, depression).
Practicalities
A Jamar-style hydraulic dynamometer runs $40–$200 retail; a clinical-grade Jamar is closer to $300. Smedley and Takei alternatives are cheaper and adequate. The test takes under two minutes once a year for a tracked baseline. Primary care offices increasingly include grip as part of an annual visit in older adults but coverage is patchy — bringing one's own measurement to the visit, or asking for the test explicitly, is often necessary.
Stakes
The forecast for the untracked weak grip is the trajectory the PURE and UK Biobank cohorts traced: a person whose grip slides from the 50th to the 10th percentile of their age band over a decade is on the curve associated with substantially elevated cardiovascular mortality and cardiovascular event rates relative to their stronger peers, accompanied by accelerating falls risk and disability incidence past age 65 (Leong et al. 2015; Celis-Morales et al. 2018; Cooper et al. 2010). The point is not that grip strength caused the trajectory; it is that the trajectory was visible cheaply and the person didn't see it.
Payoff
The payoff of measuring is informational — a tracked grip curve over decades catches the decline early enough to act on it through resistance training, protein intake, and sub-clinical-disease workup. The payoff of acting on a low reading (resistance training, protein adequacy, treating underlying conditions) is the catalogue's standard resistance-training and protein-intake payoffs, which belong in their own entries.
Out of scope
Grip training as an intervention (resistance training entry); pinch strength and finger-dexterity testing (different constructs); pediatric and adolescent grip norms (different population); pre-operative grip as a surgical-risk stratifier (clinical specialty use); grip strength in athletes (different baselines, different interpretive frame).
The credibility range
The optimist case
Grip strength is the cheapest population-scale biomarker we have for whole-body biological aging. It out-predicts systolic blood pressure for cardiovascular mortality in PURE (Leong et al. 2015), is reproducible across continents and income strata, integrates upstream health signals (muscle mass, mitochondrial function, neuromuscular integrity, cardiorespiratory fitness, sub-clinical inflammation) that no other single $50 test captures, and has been mechanistically supported by Mendelian-randomisation work showing genetic strength predicts lower CAD risk. Three major guideline bodies (EWGSOP2, AWGS, the original Fried frailty phenotype) have built diagnostic criteria around it because no alternative measure offers the same signal-to-cost ratio. For an individual tracking their own health, an annual measurement gives a trajectory no lipid panel offers.
The skeptic case
The observational hazard ratios bake in heavy confounding. People with low grip strength are systematically older, more deconditioned, less physically active, more likely to have undiagnosed disease, and more likely to be malnourished or depressed — all of which independently predict mortality. Adjusting for body size, activity, and known comorbidities does attenuate the association, and the residual signal may largely reflect sub-clinical disease that would have been caught anyway. Genetic-instrument studies (Mendelian randomisation) report causal effects roughly an order of magnitude smaller than the observational HRs, suggesting most of the observational signal is confounding. The "grip strength is a biomarker" framing also Goodharts the measurement: targeted grip training improves the reading without improving the underlying state, and the marketing of consumer dynamometers may already be pushing readers toward chasing the proxy. Finally, the cut-offs are population-calibrated and apply most cleanly to 60+ adults — for a 35-year-old reader, the test mostly produces noise.
The author's call
Grip strength is a real, well-evidenced marker of musculoskeletal and global reserve, not a causal lever to pull. The catalogue treats it as a test, not a do: a once-yearly five-minute measurement that returns a trajectory worth knowing. The evidence base is solid at the level of "low grip predicts worse outcomes" (strong, replicated, dose-response) but considerably softer at "raising your grip reading reduces those outcomes" (likely confounded; trial evidence is thin). The article's tone should be: measure, track, act on a declining trajectory through whole-body resistance training rather than gripper isolations, and read the number as a check-engine light rather than a diagnosis. Evidence score 4 (very strong observational base, weaker causal/intervention base), controversy score 1 (measurement is uncontested; what to do with it is the only mild contested area).
Stakeholder and incentive map
- Consumer dynamometer manufacturers — direct commercial incentive to market grip strength to a general audience. Devices are cheap, margins are reasonable, and Amazon visibility has grown over the past five years.
- Geriatrics and rehabilitation medicine specialty — professional incentive: the EWGSOP2 and AWGS consensus statements credentialed grip as a primary diagnostic, embedding it in clinical workflow. Workflow lock-in is real but the underlying evidence is independent.
- Longevity-focused media (podcasts, books, newsletters) — incentive to surface low-cost interpretable biomarkers; grip is a perfect fit because the test is cheap, the citations are strong, and the actionable advice (resistance training) is already in the genre's playbook.
- Primary care — modest incentive against routine adoption (time pressure, no billing code in many jurisdictions, no clear treatment threshold). Adoption has been slow despite guideline support.
- Skeptics / critics — academic gerontologists who argue the marker is informative but treated more confidently than the evidence warrants, particularly when extrapolated to under-60 populations. The "Goodharting the proxy by training the proxy" critique is recurring and reasonable.
Population variability
- Age. Predictive power is strongest in 60+ adults, where grip co-segregates with frailty and sarcopenia diagnostic criteria. Under 40, grip predicts mortality at population scale but the single-reading signal-to-noise for an individual is weak; trajectory matters more than absolute value.
- Sex. Men have ~50% higher absolute grip than women across all ages; the mortality slope vs grip is similar within sex strata. Cut-offs are sex-specific.
- Ethnicity. AWGS 2019 cut-offs (Chen et al. 2020) differ from EWGSOP2 by several kilograms. South Asian populations tend to test lower than European populations at similar functional status; using European cut-offs over-diagnoses weakness in South Asian cohorts.
- Body size. Grip correlates with body mass; absolute grip favours larger individuals. The Fried frailty phenotype adjusts grip for BMI to correct for this; epidemiological studies typically don't, which inflates absolute differences.
- Occupational baseline. Manual workers, instrumentalists, and rock climbers test substantially above sedentary baselines without that signalling lower mortality risk. The interpretive frame for athletes is different.
- Hand pathology. Severe arthritis, post-surgical hands, advanced neuropathy, and Dupuytren's distort the reading independent of global reserve.
Knowledge gaps
- Intervention evidence is thin. Few RCTs have asked whether raising grip strength (via resistance training, nutritional intervention, or both) reduces hard outcomes; the observational base does not by itself license a causal claim for the inverse.
- Cut-offs under age 60. The diagnostic literature is anchored at 65+. Population reference values exist (Bohannon, JOSPT 2018) but evidence-based action thresholds for 30–60 year-olds are not established; the marker is best read as a trajectory in this band.
- Optimal measurement frequency. No strong evidence on whether annual, biennial, or longer-interval measurement maximises predictive value for an individual. Annual is the practical default by convention, not by trial evidence.
- Goodharting risk. No empirical work, to the author's knowledge, on whether widespread consumer adoption with targeted grip-only training has degraded the marker's predictive value at the population level.
- Mendelian-randomisation precision. Current MR estimates of grip's causal effect on CVD are imprecise; instrument strength is moderate and pleiotropy plausible. The causal magnitude question is open.
Scope call. The brief asked for "hand grip strength measured in adults" plus its correlation with cardiovascular risk, all-cause mortality, frailty, and functional decline. The article covers all four — CV and all-cause mortality lead the evidence section, frailty surfaces in audience and misconceptions (the Fried phenotype anchor), and functional decline runs through stakes and payoff. No silent narrowing.
Action and category. Treated as test (measure and track), not do (train). Grip training is a downstream response and gets its own home in resistance-training entries; the literature on grip training improving the proxy without improving outcomes (the Goodharting risk) is the reason to keep the entries separate. Category is screening rather than exercise for the same reason.
Longevity score (4 not 5). The PURE / UK Biobank / Cooper et al. base would justify a 5 if the measurement itself reduced mortality. It doesn't — what reduces mortality is the action the reader takes in response. The test is a high-quality detector of a high-stakes signal, which puts it firmly at 4. A 5 is reserved for interventions that bend the population curve when widely adopted.
Health_short_term score (2). Wavered between 1 and 2. Landed at 2 because the catch-it-early case for treatable contributors (depression, malnutrition, sub-clinical disease) is real even if the dynamometer reading itself doesn't make anyone feel better in weeks.
What was excluded. (1) Pre-operative grip strength as a surgical-risk stratifier — clinical-specialty use, not a general-reader concern. (2) Pediatric and adolescent grip norms — different population, different interpretive frame. (3) Pinch strength and finger dexterity — different constructs. (4) Grip strength in elite athletes / climbers / instrumentalists — the interpretive frame doesn't transfer.
Future-link candidates. Once these entries exist, wire them into out-of-scope: resistance-training, protein-intake, vo2max-testing, annual-bloodwork, sarcopenia, frailty.
Separate-entry candidate. sarcopenia warrants its own entry — grip is one diagnostic input, but sarcopenia covers a larger substance (muscle loss with aging) with its own protocol surface (resistance training plus protein dosing plus sometimes pharmacology). Flagged for the backlog.
Hard call on causation framing. The Mendelian-randomisation literature supports a small causal effect of grip on CVD; the much larger observational hazard ratios are heavily confounded by overall fitness and sub-clinical disease. The article addresses this explicitly in misconceptions rather than burying it — the catalogue's voice depends on not overselling. Evidence rating reflects the asymmetry: very strong prediction, weaker causation, thin intervention evidence.
No contraindications token. The closed contraindications vocabulary doesn't include hand/wrist pathology, which is the only situation where the measurement itself is contraindicated. Mentioned in the research dossier; not raised in the article body because it's narrow and primarily affects measurement validity, not safety.
Grip Strength as a Health Marker
A hand dynamometer costs about $50 once and lasts decades.
Two minutes once a year. Three squeezes per hand, write the best one down.
Across hundreds of thousands of adults, weaker grip predicts dying sooner — earlier heart attacks, earlier strokes, earlier from almost any cause — better than blood pressure does.
Two of the largest health studies ever run (PURE, UK Biobank) say the same thing, and major medical bodies now use this number to screen older adults.
A weak or falling reading is often the first sign of quiet deconditioning, poor nutrition, or undiagnosed illness — soon enough to do something about it.